ArticleJACC. Asia2025
Body Mass Index and Outcomes After Transcatheter Aortic Valve Replacement: Insights From the Transpacific-TAVR Registry.
Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Incidence and Factors Associated With In-Hospital Acute Myocardial Infarction in Patients With Obesity Undergoing Transcatheter Aortic Valve Replacement: A National Inpatient Sample Analysis.Cardiology research · 2026Article
- BMI Is Unreliable When Studying the Obesity Paradox in TAVR.JACC. Asia · 2026Article
- Reply: BMI is Unreliable When Studying the Obesity Paradox in TAVR.JACC. Asia · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhereas some studies suggest an "obesity paradox" with improved outcomes in obese patients following transcatheter aortic valve replacement (TAVR), the impact of pre-TAVR body mass index (BMI) and post-TAVR BMI changes on clinical and echocardiographic outcomes remains unclear.
objectivesThis study sought to evaluate the influence of BMI at the time of TAVR and subsequent BMI changes on clinical and echocardiographic outcomes in patients undergoing TAVR.
methodsWe included 1,339 patients with severe, native aortic stenosis from 2015 to 2019, stratified by BMI according to World Health Organization classifications, from an international registry. The primary outcome was overall survival, with secondary outcomes including short- and long-term survival, bleeding, vascular injury, stroke, and acute kidney injury. Descriptive statistics and time-to-event analyses were performed.
resultsUnderweight patients were older (n = 45; age 83.8 ± 6.6 years) compared to normal weight (n = 576; 81.5 ± 7.0 years), overweight (n = 438; age 81.0 ± 7.4 years), and obese (n = 280; age 77.4 ± 8.3 years; P < 0.001) patients. Underweight patients had the highest rates of chronic kidney disease (66.7%) and moderate or greater aortic regurgitation (28.9%). Obese patients had the highest rates of atherosclerotic cardiovascular disease risk factors. Over a median follow-up of 1.1 (Q1-Q3: 0.6-2.7) years, there were no significant differences between BMI groups (P = 0.69). At 1-year follow-up, underweight patients showed improved left ventricular remodeling and favorable TAVR hemodynamics.
conclusionsPre-TAVR BMI did not significantly affect clinical outcomes in this diverse cohort, challenging the obesity paradox. However, underweight patients exhibited subtle improvements in left ventricular remodeling and valve hemodynamics post-TAVR, highlighting a nuanced role for BMI in recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.